Company

Celcuity Inc.

Headquarters: Minneapolis, MN, United States

Employees: 39

CEO: Mr. Brian F. Sullivan

NASDAQ: CELC -2.73%

Market Cap

$432.9 Million

USD as of Jan. 1, 2025

Market Cap History

Celcuity Inc. market capitalization over time

Evolution of Celcuity Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Celcuity Inc.

Detailed Description

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date Dec. 31, 2023
Revenue TTM $0
EBITDA $-66,087,560
Gross Profit TTM $0
Profit Margin 0.00%
Operating Margin 0.00%
Quarterly Revenue Growth %
Financial Reports & Statistics

Stocks & Indices

Celcuity Inc. has the following listings and related stock indices.


Stock: NASDAQ: CELC wb_incandescent

Details

Headquarters:

16305–36th Avenue North

Suite 100

Minneapolis, MN 55446

United States

Phone: 763 392 0767